Acute faecal incontinence with diarrhoea (AFId) has been reported to affect up to 40% of patients in the intensive care unit (ICU). The clinical challenges of AFId include the risk of perineal skin breakdown and cross-contamination with nosocomial infections, such as Clostridium difficile. In addition, the management of AFId is a burden on nursing time and hospital resources. Despite these challenges, there is currently no standard way of managing AFId. To address this problem, an international panel of intensive care specialists was convened to discuss AFId management recommendations. The collective knowledge of the specialists combined with literature searches from online medical databases were used to create a set of guidelines together with an accompanying management algorithm to aid healthcare providers in deciding the most appropriate care for patients with AFId in the ICU. These guidelines have been specifically designed to take into account patient severity of illness and comorbidities, which coupled with common AFId-associated clinical complications, can influence management choices. A comprehensive review of current AFId management strategies, taking into account the spectrum of patients and hospital economic limitations, has been included as a reference guide. It is hoped that the wider adoption of these recommendations will be a step forward in improving the current management of AFId in the ICU.
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The present initiative is sponsored by ConvaTec as part of a commitment to better understand and address key challenges in the management of acute faecal incontinence in the intensive care setting.
Introduction
Acute faecal incontinence is often associated with diarrhoea (AFId) in ICUs; 1 however, there is a lack of information on the incidence and prevalence of the condition in such settings. 2 In the ICU there are a number of clinical challenges associated with AFId, including the risk of conditions such as perineal dermatitis, skin breakdown, development of pressure ulcers, sepsis, as well as cross-contamination with pathogens responsible for healthcare associated infections (HCAIs). 3 In addition to these clinical risks, the management of AFId requires considerable use of nursing time, with increases in hospital length of stay and costs resulting from the management of complications. [4] [5] [6] [7] While there are a number of management strategies available to healthcare providers, it is important to take into account not only the degree of severity or the risk of developing complications, but also patient dignity and quality of life. 8, 9 The FIRST (Faecal Incontinence Re-evaluation Study) Survey (sponsored by ConvaTec Inc), a cross-sectional study carried out in ICUs in four European countries assessed the current prevalence of AFId, awareness of its associated clinical challenges, and management strategies currently being used to manage AFId. 10 The prevalence of AFId ranged from 9-37% of patients on the day of the survey, depending on the country. A low level of awareness of the clinical challenges and substantial variability in the management strategies to manage AFId were reported. Additionally, the survey reported that there appeared to be a lack of, and a need for, AFId management recommendations in the countries surveyed.
For these reasons, these recommendations have been prepared to provide information to healthcare providers in the ICU to allow them to provide the best care for AFId patients, as well as to help reduce unnecessary time and costs being expended on managing AFId. The wide adoption of these recommendations will be a step forward in improving the current management of AFId.
Methods
A panel of healthcare professionals from across Europe (sponsored by ConvaTec Inc), with known interest in the issues of skin breakdown and infection in ICUs, was invited to examine the issue of faecal incontinence in ICU patients. They included ICU specialists, ICU nurses and infectious disease specialists. They reviewed the current knowledge of AFId with the aim of providing recommendations for its management. The panel agreed a management algorithm for use in any patient experiencing AFId, which is presented here (Figure 1 ).
Literature searches were performed using the National Library of Medicine Electronic Database, Pubmed, to supplement the collective knowledge gathered at the meetings. Database search parameters comprised combinations of keywords, including 'faecal incontinence,' 'diarrhoea,' 'intensive care unit,' 'ICU' 'critical care,' 'acute,' 'dermatitis,' 'cross contamination' and 'management.'
The panel first met in Barcelona in December 2011. An outline summary was drafted based on the discussions at this meeting, which was then assessed and amended by each member of the panel. In addition, roundtable meetings were held in the UK, Italy, Spain, Germany and the Nordic countries where local experts (eg ICU specialists, infection control specialists, burn specialists and graft-versus-host disease (GVHD) specialists) were given the chance to provide feedback and to contribute further ideas to the document. Comments were consolidated and implemented into the revised document. A complete list of the specialists who attended the round table meetings is in the Appendix.
The recommendations were discussed at an additional advisory board with the expert panel, where the final revisions were agreed.
AFId and its clinical consequences

Definition of AFId
The World Health Organisation describes diarrhoea as 'the passage of three or more loose or liquid stools per day, or more frequently than is normal for the individual.' It is usually a symptom of gastrointestinal infection caused by a variety of bacterial, viral and parasitic organisms. 11 In contrast, faecal incontinence has no fixed description. A range of definitions has been used over the years, differing in detail or scope depending on the circumstances in which it occurs. For example, the Royal College of Physicians 12 describes it as 'the involuntary or inappropriate passage of faeces,' while Kenefick 13 defines it as the 'uncontrolled passage of solid or liquid faeces at socially inappropriate times and places.' 14 The World Health Organisation Consultation on Incontinence 15 incorporates additional factors into its definition when stating that 'anal incontinence is the involuntary loss of flatus, liquid or solid stool that is a social or hygienic problem.'
For the purpose of these recommendations, and to differentiate between other, more heterogeneous definitions of faecal incontinence that are not relevant to the ICU, a standardised definition of AFId was proposed by the expert group who originally designed the FIRST TM survey and agreed by the expert panel. 'AFId' is thus defined as 'when a patient experiences at least two episodes of faecal incontinence with diarrhoea -liquid or semi-liquid stool (according to the Bristol Stool chart 16 ) -in a 24-hour time period'. It should be noted that AFId does not refer to continent patients with diarrhoea who are still able to use toilet facilities.
Causes of AFId in the ICU
In the ICU a number of determinants exist that put the patient at a higher risk of developing AFId. A leading cause is the use of antibiotics, especially in cases where numerous such medications are administered. 6 The alteration of normal intestinal flora by pharmacological agents can lead to the opportunistic colonisation with pathogens such as Clostridium difficile (C. difficile), thereby promoting the onset of diarrhoea and encouraging crosscontamination. C. difficile infections are responsible for 15-25% of diarrhoea cases in the ICU. 6 A second leading cause of diarrhoea in the ICU is enteral feeding. 4, 17 Some functional factors that can complicate or indeed promote AFId episodes, include impaired cognition, decreased mobility, altered communication abilities and sedation. 4 High-risk patients include the frail and elderly, patients who have received radiation therapy of the pelvic floor, those presenting with diarrhoea or loose stools from any source, and patients who have undergone colonic resection or anal surgery. 18 Further causative factors include: drugs (including laxatives, lactose-or sorbitol-containing products, non-steroidal antiinflammatory drugs, prostaglandins, colchicine, antineoplastic agents, anti-arrhythmic drugs and cholinergic agents); 19 chemotherapy; graft-versus-host disease; 20 hypoperfusion of the gut; malabsorption syndrome; and viruses (such as norovirus and rotavirus). 21 
Systemic effects
AFId can have a substantial effect on electrolyte balance. Fluid loss due to a large amount of liquid stool can compound other sources of electrolytic imbalance such as fever, gastric stagnation, perspiration, third-space losses, ascites, pulmonary oedema and pleural effusion.
AFId may therefore trigger a domino effect in critically ill patients, worsening their clinical status by decreasing total body water, leading to acute kidney injury or precipitating hypovolemic, cardiogenic or septic shock. The electrolytic imbalance can cause brain oedema and mental status alteration (hyponatremia), cardiac arrhythmias (hypokalemia), asthenia and myoclonus and seizures (hypernatremia). The faster the onset of electrolyte imbalance, the more probable the complications. 4 
Local effects
There are also local effects that AFId has on the patient, including the risk of skin breakdown and increased skin colonisation with potential pathogens. Skin colonisation is a risk factor for infections related to invasive devices. 4 
Skin breakdown
One of a number of complications associated with AFId is the risk of skin breakdown around the perineal and sacral area. Skin breakdown is categorised in terms of severity, ranging from superficial irritation, to deeper tissue and muscle damage (such as pressure ulcers), skin infections that in turn can become systemic, causing sepsis and ultimately possibly, death. 4
Causes of skin breakdown in AFId patients
Similarly to skin problems associated with urinary incontinence, which leads to maceration of the skin and promotes enhanced colonisation of bacteria, liquid stool in contact with the skin can cause significantly more irritation as bacteria and enzymes present in the stool cause direct damage to the skin. 22 It has been reported that hospitalised patients with faecal incontinence are 22 times more likely to experience skin damage (defined in the study as pressure ulcers) than patients without faecal incontinence. 23 One of the main risks for the development of ulcers in such patients is the persistent contact of moisture with the skin. When the skin is exposed to liquid for prolonged time periods, it becomes waterlogged, causing it to become soft and wrinkled, and increasing its friction coefficient. 14, 24 As a result, the protective barrier of the skin is breached, which leaves the patient prone to attack from pathogens, most notably those already present in the stool in contact with the skin. 25 The risk of skin damage depends on the frequency and volume of the stool and the management strategy for the incontinence. For example, incontinence pads trap moisture next to the perineal skin, leading to perspiration, which may further increase the local moisture content adding to water-logging and compromised skin integrity. 22 The pH of skin is normally slightly acidic (pH 5.5), but becomes more alkaline in the presence of urea and ammonia in liquid stool. 26 Bacterial growth in this environment can further increase skin pH, in turn exacerbating the risk of dermatitis or skin excoriation. The use of a pad can increase this risk further, as the pH of the skin may rise to around 8 as stool and perspiration is trapped in contact with the skin. 14, 22 The maintenance of this moist environment next to the skin is a significant risk factor for the formation of pressure ulcers. 27 
Definition of the different manifestations of skin breakdown
For the purpose of these recommendations, skin breakdown will be discussed in terms of three main conditions: namely, the presence of incontinence-associated dermatitis (IAD), the development of moisture lesions due to the maceration of the skin, or pressure ulcers (PUs).
A consensus statement released in 2007 sought to standardise the definition for IAD as 'inflammation of the skin that occurs when urine or stool comes into contact with perineal or perigenital skin.' 28 The distinction between a pressure ulcer and a moisture lesion is not simple, however. This presents difficulties for healthcare professionals who need to be able to distinguish one from the other, as the management for each is different. 29 In 2009, the European Pressure Ulcer Advisory Panel (EPUAP) released the following definition of pressure ulcers: 'a pressure ulcer is a localised injury to the skin and/or underlying tissue usually over a bony prominence, as a result of pressure, or pressure in combination with shear.' 27 In contrast, a moisture lesion has been defined as 'skin damage resulting from exposure to excessive moisture, associated with incontinence, but not caused by pressure or shear.' 14 While PUs tend to form over a bony prominence, a moisture lesion tends to be spread out over a larger area. 29 However, PUs and incontinence lesions can often co-exist and are then known as combined lesions.
Since the EPUAP publication in 2009, a group of UK clinicians (sponsored by ConvaTec Inc) have developed a diagrammatic tool that can be used to help identify the type of skin damage. 30, 31 The use of this chart can help clinicians to identify the type and level of tissue damage present and help them to choose the skin-care regimen best suited to managing the patient.
Pressure ulcers can be further grouped into categories in order to distinguish different levels of injury. 27 Category 1: non-blanchable erythema, described as intact skin with non-blanchable redness of a localised area over a bony prominence. Category 2: partial thickness loss of the dermis. Category 3: full thickness tissue loss, where subcutaneous fat may be visible but bone, tendon or muscle is not. Category 4: full thickness tissue loss, where bone, tendon or muscles are exposed.
It is important to distinguish between IAD and PUs in order to give the most appropriate care to the patient. While similarities exist between category 1 PU and IAD, in IAD the borders of erythema are more irregular and dispersed throughout the area exposed to the urinary or faecal incontinence. 32 A PU tends to be a discrete, circular lesion with distinct edges and can be of full thickness (whereas an IAD is diffuse with irregular edges), is found more in skin folds, may cause pruritus, and when on the buttocks, may have a 'puckered' shape.
Prevalence of skin breakdown
A small number of studies have reported the prevalence of skin breakdown in critically ill patients. Junkin and Selekof 33 examined IAD in 608 adult and paediatric patients in a one-day study of a number of units (including the ICU) in two US hospitals. They report that 20% of 120 incontinent patients presented with IAD, one of whom was not faecally incontinent (23/24).
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© The Intensive Care Society 2013 Driver 34 observed IAD in 308 adult patients with faecal incontinence in a medical-surgical intensive care unit. IAD was defined as any redness, weeping, or denudement of the skin. Of the patients observed, 10% (32 out of 308) of patients had faecal incontinence, and 34% of those (11 out of 32) had IAD.
The FIRST TM survey on the estimated prevalence and clinical consequences of AFId in ICUs in four European countries revealed that approximately 26% of ICU personnel reported that the AFld patients had perineal dermatitis, 21% reported patients with moisture lesions, and 16% reported that patients with AFId suffered from pressure ulcers. 10 
Risks and clinical consequences
The risks of skin breakdown in patients with AFId are numerous and can be very distressing. 35 Additionally, the friction associated with skin breakdown contributes to substantial discomfort as the skin becomes sensitive when the patient moves around on the bed or when being dressed. 25 The caregivers involved in the management of AFId episodes need to be aware of fragile perineal skin that may become further compromised due to friction caused by wiping away the existing stool, or when removing garments or protective barriers that may have adhered to the wounded skin.
In addition, further problems arise when the pathogens that gain entry to the wound penetrate deeper into the tissue and enter the blood stream causing systemic infections supplementary to the patients' existing illness. 4 
Infection and cross contamination
AFId is associated with contamination and colonisation of the perianal area by microorganisms and wounds as a consequence of skin breakdown. This area may become infected and act as a portal of entry for invasive infections. 4, 28 Another risk factor for infection is the incontinence management strategy, such as the placement or removal of urinary catheters.
Healthcare associated infections (HCAIs) and their risk factors in the ICU
Clostridium difficile, particularly PCR ribotype 027, is responsible for 15-25% of cases of ICU-related diarrhoea. 6, 36 This anaerobic bacterium has been identified as the leading cause of healthcare associated diarrhoea in adults and can be responsible for outbreaks in the ICU.
One of the main causes of C. difficile-associated diarrhoea (CDAD) is the use of antibiotics to treat or prevent other infections. Almost all antibiotics have been implicated in the development of CDAD in the ICU, particularly broad-spectrum antibiotics administered orally. 6 In addition, advanced age, gastrointestinal surgery or underlying illnesses are risk factors. Anything that interferes with the barrier in place with the normal flora, which prevents the entry of opportunistic pathogens, will increase the risk of CDAD; this includes the long-term use of broad-spectrum antibiotics.
The use of antibiotics has also been implicated in the spread of other pathogens in the ICU, such as vancomycin-resistant enterococci (VRE). A study conducted in two ICUs in the USA reported that increased environmental contamination with VRE contributed to the increased incidence of diarrhoea following VRE colonisation, whereas the use of no antibiotic was strongly protective. 37 The patients in the study whose rooms were contaminated were more likely to have had diarrhoea than those who were not contaminated, and were also more likely to have been exposed to antibiotics. However, another study noted that both stool-continent and incontinent patients were equally likely to contribute to ICU contamination, suggesting that similar infection control methods should be implemented for all VREpositive patients in the ICU. 38 Since it is not uncommon for CDAD patients to be infected concurrently with VRE, studies have been carried out to compare the use of different treatments to avoid the colonisation by and spread of VRE. One such study of patients in acute and long-term care reported that in VRE-colonised patients with CDAD who experienced frequent faecal incontinence, skin and environmental VRE contamination was common during and after the resolution of diarrhoea episodes. 39 The frequency of VRE contamination was found to be similar between patients treated with metronidazole and those treated with vancomycin.
Further problems of environmental contamination associated with diarrhoea have also been reported for patients infected with meticillin-resistant Staphylococcus aureus (MRSA). 40 A prospective, observational study reported that patients who have diarrhoea and heavy gastrointestinal colonisation with MRSA have significantly greater environmental MRSA contamination rates than patients without MRSA in their stool.
While C. difficile accounts for the majority of nosocomial diarrhoea outbreaks, other pathogens have been implicated. Such organisms include cryptosporidium, 4 extended-spectrum betalactamases and E. coli. 41 In addition, there are viral causes for diarrhoea, including norovirus -a major cause of viral gastroenteritis -cases of which can put significant economic strains on hospitals. 42 
Clinical consequences of HCAIs in patients with AFId
There are three main groups affected by AFId caused by HCAIs: the patient, the ICU environment, and the healthcare workers managing the AFId episodes. For the patient, HCAIs often lead to a perpetuation of AFId episodes, which may alter the patient' s electrolyte balance, leading to the problems associated with skin breakdown listed above, and increasing the length of hospital stay. 4 Specifically with C. difficile infections, there is a wide spectrum of associated clinical features, ranging from uncomplicated diarrhoea to life-threatening complications such as pseudomembranous colitis, toxic megacolon and intestinal perforation, possibly leading to severe sepsis and/or bacteraemia. 43 In the patient' s environment as we have seen, the risk of crosscontamination increases with CDAD episodes. For example, the floor and bedrails in close proximity to patients have been shown to be a primary source for transmitting pathogens, thus promoting the transmission of CDAD to other patients in the ICU which may create an outbreak that becomes hard to contain. 44 One prospective study quantified this by showing that an infected patient can cause their roommate to become infected on an average of 3.2 days after admission compared with 18.9 days in the absence of infection. 45 This same study also highlighted the importance of handwashing, as C. difficile was found on the hands of 59% of hospital staff caring for infected patients. The risk for hand-to-surface cross-contamination is substantially increased in such situations. There is also the risk that C. difficile spores may be transmitted through the air, with one study reporting the isolation of spores from the air around seven of 10 patients and surfaces surrounding nine of 10 patients infected with C. difficile. 46 For nurses, the burden of time and costs of materials is increased substantially when there are multiple CDAD infections to be managed. 10 
Patient experience/dignity
AFId also has as an impact on the quality of life and dignity of both the patient and the patient' s family. 30 Incontinence and its effects, such as unpleasant odours, carries the stigma of being undignified and embarrassing and may result in significant psychological distress for the individual. 48 As well as causing embarrassment and inconvenience, it threatens a patient' s selfesteem and self-confidence due to the loss of personal control and modesty. Maintenance of privacy and dignity is vital when caring for patients suffering from AFId. 14 The trend in ICU practice is to keep patients more awake, administering effective analgesia where necessary but avoiding excessive or unnecessary sedation. This is to avoid critical illness myopathy and neuropathy, to minimise the risk of aspiration that may lead to ventilator-associated pneumonia, 49 and to decrease time on mechanical ventilation. When the patient is awake, they will experience stressful events (eg noisy environment, device insertion, invasive procedures, etc). AFId may precipitate psychological problems from loss of dignity and independence. The need for two or three nurses to remove the faeces and clean the patient may be depressing and frustrating. 4 There is an increasing trend to allow open visiting for a patient' s family in the ICU. This may mean that family members may witness episodes of AFId being managed, which may cause additional stress and anxiety.
Faecal management options for patients with AFId
The following describes the management strategies that are available to healthcare workers to manage AFId. Information regarding the most appropriate implementation of such methods can be found below.
Traditional management methods
Pads and incontinence sheets
Pads and incontinence sheets are designed to contain diarrhoea and, in some cases, absorb liquid stool. 4 
Advantages/disadvantages
These are the cheapest and most simple way of managing episodes of faecal incontinence and are often offered as a first-line strategy. 4, 18 When well-fitting, they are able to prevent leakage but it is important that caregivers are vigilant in changing them regularly as they are not effective in containing the unpleasant odours from leaking stool. If not combined with regular washing of the soiled skin and state-of-the-art moisturisers and skin barrier products, they can be responsible for the development of skin breakdown and its associated problems, as explained above. 4 In addition, pads and incontinence sheets may increase the risk of transmitting infectious material and spreading HCAIs because of the constant replacement and disposal of soiled devices, as well as cleaning of soiled skin and changing contaminated bedding. For this reason, this management method is inadequate as a long-term management strategy for AFId. 41 The efficacy of pads and a faecal management system (FMS; discussed below) in the containment of C. difficile-infected diarrhoea was tested in an in vitro system set up to simulate the clinical use of an FMS device. While vertical leakage of spores through the pads was not observed, wicking of the liquid stool across the absorbent surface to the edge of the pad, leading to lateral spread and leakage beyond the pad perimeter, suggested suboptimal containment properties for this method. 50 In contrast, spores were recovered neither from the outside of the FMS device nor from the air or surfaces around the device, indicating that the containment properties of an FMS were significantly better than the pad.
When to use pads NICE guidelines suggest the use of a pad as a first-line management strategy in patients with faecal incontinence. 18 However, the All-Wales Guidelines for Faecal Management Systems acknowledges that these methods are not appropriate for every patient. 14 Indeed, additional studies declare that the use of pads is not recommended in the management of AFId due to the large volume of waste generated, which increases the risk of crosscontamination, skin breakdown and the increased nursing time needed to clean the patient and change bedding. 41 
Time required to manage AFId with pads and cost considerations
While the cost of individual pads may be low and the time for staff training short, the costs of managing frequent and persistent AFId episodes can be significant. This takes into consideration the time spent by care providers to manage each episode, the large number of replacement pads used, and the additional costs of managing the spread of infections through inadequately contained, infected faeces. 4, 9, 51 Faecal collection devices Faecal collection devices collect liquid stool away from the skin, reducing the risk of IAD and other skin complications. 41 A faecal collector is comprised of a tape border that adheres to the perianal area, which is in turn attached to a pouch to allow the collection of liquid stool (Flexi-Seal TM Faecal Collector product summary). The pouch may also be equipped with a drainage tap, which can be connected to a bedside drainage collector, and/or a deodorising filter.
Faecal collectors are used on non-ambulatory patients who are incontinent of loose or semi-formed stool. The aims of a faecal collector are as follows: 52 • To safely divert faecal matter away from a patient' s skin • To protect wounds from faecal contamination • To reduce skin breakdown • To reduce the spread of infection.
The collection pouch is entirely external and non-invasive. It therefore carries no risk to the internal anal continence mechanisms and to the rectal mucosa that can accompany use of devices that cross the anal sphincter and dwell in the rectal vault. 4 In contrast to FMS (discussed below) the faecal collection device is much cheaper.
The major disadvantage of using a faecal collection device concerns its adhesion, or how well it is able to remain in place. Adhesion can be jeopardised by perspiration, residue from soaps and cleansers and the products used to treat skin breakdown, such as moisture barriers, lotions, and ointments. 4 Removal of the device may also result in skin tears and abrasions. 53 Faecal collection devices are not useful and may even be harmful for patients who are ambulatory, agitated, or who move around in bed, because the apparatus may become dislodged. If this goes unnoticed, the skin may break down, infected stool may leak and further applications of the device may be ineffective. 4 In addition, the application of a faecal collection device requires at least two caregivers to apply correctly. 54 
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Faecal management systems (FMS)
Faecal management systems (FMS) are designed to divert faecal waste to a collection bag away from the patient, thus reducing soiling, preventing the spread of infectious microorganisms and helping to preserve skin integrity. The FMS is a temporary faecal diversion and containment system that consists of a soft flexible silicone tube approximately 1.55 meters long, with a soft silicone catheter at one end that is inserted into the patient' s rectum, and kept in place by a low pressure retention balloon. A collection bag is located at the other end for containment of faecal waste, which is changed as needed.
An FMS is indicated for patients with liquid or semi-liquid stool and little or no bowel control. 55 While an FMS has the same advantages as a faecal collection device, it also has a number of superior attributes. One important advantage compared to faecal collectors is that indwelling FMS devices can prevent further deterioration of skin integrity in those with existing IAD 54 by preventing contact of liquid stool with the skin, as well as avoiding the pain and further breakdown of the skin associated with applying and removing the external collection system.
The shape, size, and softness of the rectal balloon of the FMS are designed to minimise mucosal damage after insertion into the rectum. The device can be retained in the rectum for up to 29 days. In a US-based evaluation of the safety of an FMS device, of 42 patients, 35 were able to retain the FMS until removal, and the device was reinserted successfully in three of the seven patients who expelled it. 54 Furthermore, 92% of patients experienced no further deterioration and even showed improved skin integrity when using an FMS. The rectal mucosa was also seen to remain healthy. In order to prevent damage caused by over-inflation of the retention balloon, certain FMS devices are equipped with an indicator to guide the clinician in finding the appropriate fill level.
Importantly, some FMS devices have been shown to contain C. difficile, which substantially reduces the contamination of bedding, surgical/nursing instruments and the risk of cross contamination with HCAIs. 8, 50 This therefore reduces the need to physically isolate the patient in order to prevent infecting other patients in the ICU, as well as reducing nursing time spent managing AFId episodes and improving patient dignity.
The redirection of faecal matter also reduces the unpleasant odour associated with leaking stool. 52 This is especially true in certain FMS models where the collection bag contains a deodorising filter. Furthermore, the inclusion of a scale on the side of the collection bag provides a way of monitoring fluid loss.
Appropriate use of FMS
There are a number of FMS products that may be used, each with specific indications and contraindications. The choice of which FMS can thus be made depending on both manufacturer recommendations and expert experience. There are occasions when the use of FMS products is inappropriate, for example, in mild, resolving gastroenteritis. They are not suitable in cases where the stool is dense and unable to drain, because the device may become blocked and its efficacy compromised. They are also contra-indicated with certain lower bowel conditions and surgery, where there are risks of causing harm on insertion of the product into the rectum, which may lead to rectal bleeding. 35 There are risks of anal injuries and bleeding, of which there are case reports in the literature. [56] [57] [58] There is also concern about how the long-term use of these devices may affect anal sphincter tone, as well as the risk of infection, bowel obstruction, and abdominal distension. 14 
Time required to manage AFId with FMS devices and cost considerations
A small number of studies have directly addressed the costs of FMS devices in terms of material and time. 7, 51 In comparison with traditional methods for dealing with faecal incontinence, the initial high cost of FMS devices can be offset by the savings made in nursing time, as well as the use of cleaning materials, linen and laundry used to manage episodes of AFId.
The high costs of managing pressure ulcers 59 and C. difficile infections 60 can also be reduced through the use of FMS devices. As explained above, FMS devices have been shown to reduce skin deterioration 14 and successfully contain infectious stool. 8, 50 
Expert recommendations for the management of AFID in the ICU
The following is a set of recommendations to help healthcare professionals manage AFId episodes in the ICU. Building on the review of the literature and the evidence presented above, these recommendations acknowledge the wide range of patients who present with AFId and how their co-morbidities can often complicate management choices. In order to facilitate these choices, an algorithm has been developed to aid healthcare professionals (Figure 1) . The most appropriate choice of care for different patients can then be made, with the aim of preventing or reducing the clinical consequences of AFId while optimising nursing time and preserving patient dignity.
The following text is a guide for healthcare professionals to help them navigate through the algorithm. Each part of the algorithm will be explained and management pathways for different patients will be followed. For each possible pathway, there will be an explanation of how the management choices described above can be chosen depending on the severity of the patient' s condition and their clinical risks.
Patient assessment
Once a patient has been diagnosed with AFId, a full patient assessment should be carried out. A comprehensive patient assessment allows the categorisation of patients in terms of the severity of their AFId symptoms, their clinical situation, the risk or presence of complications that may be associated with AFId, and also patient comfort and dignity.
Patient comfort and dignity
Faecal incontinence is a stigmatising condition that can affect the dignity and self-esteem of the patient, often causing significant embarrassment and psychological trauma. 48 In the ICU it is therefore of paramount importance that the patient is kept comfortable and that their dignity is maintained as part of a successful management programme. 14 According to one report, patients, relatives and staff acknowledged that the use of an FMS device was associated with psychological benefits due to reduced emotional trauma and embarrassment, coupled with an increase in physical comfort and dignity of the patients. 7 The morale of the staff can also be affected by the stress of dealing with anxious patients and family members affected by episodes of AFId. 35 In order to provide the best care to their patients, ICU staff need to have a thorough understanding of AFId and feel properly equipped, both emotionally and physically, to deal with its issues. 
The algorithm
When developing the management algorithm, the expert panel agreed on the categorisation of patients into two groups according to the severity of AFId and the associated clinical risks (Figure 1 ).
AFId with, or at risk of developing, complications
The patients in this group are those considered to be at risk of developing complications related to AFId, or those presenting with complications such as skin breakdown. These patients are most suitable for management with FMS.
Patients should also be assessed for wounds that may be at risk of infection or further breakdown, such as burns, post-operative wounds and Fournier' s gangrene, which, due to its occurrence in the perineal area, will cause additional complications when present with AFId.
The use of antibiotics is known to disrupt gut flora and provoke more frequent, intense C. difficile-induced AFId episodes, which can lead to the spread of infection. Diarrhoea may also be the result of a concurrent medical condition, such as pancreatitis, or may also be induced, for example, with laxatives prescribed to treat conditions such as hepatic encephalopathy. The prolonged presence of diarrhoea exacerbates all the previously described conditions, such as skin breakdown and environmental contamination/cross-infection as well as putting strains on nursing resources and causing signific distress for the patient and those around them.
An additional high-risk group includes immobile patients, such as those with severe respiratory failure, multiple trauma, those receiving extracorporeal membrane oxygenation (ECMO), or the morbidly obese. The increased risks of AFId-associated complications in this subgroup are due to extended periods of immobility or prone positioning, which promote the development of pressure ulcers.
Furthermore, patients with poor nutritional status who require enteral nutrition (EN) are also at high risk, as EN can cause AFId. In palliative care, an FMS can also be considered to help preserve
Diagnosis of AFId
A second episode of faecal incontinence with diarrhoea (liquid or semi-liquid stool, Bristol stool chart type 6-7) in 24 hours
AFId with or at risk of developing complications, eg:
Risk of skin breakdown in perineal region, eg: the dignity of the dying patient and their family. Before an FMS is used, all healthcare workers expected to work with the device should familiarise themselves with the correct operating procedures and undergo training for its use. Potential problems associated with misuse are described above. In addition, healthcare workers should also make themselves aware of the various indications and contraindications for the use of different FMS devices as described by their manufacturers, since different devices may be unsuitable for certain patient groups.
AFId with a good prognosis
The second group comprises patients who are deemed to have a good prognosis that AFId will resolve, those with a low risk for skin damage or environmental contamination, or those for whom it has been decided that more complicated management strategies are unnecessary. Patients in this group include those who are wellnourished or well-hydrated and those not expected to remain in hospital for a long time due to the imminent resolution of their symptoms. Patients who are predicted to have a short life expectancy are also included in this group; however, it is still important to maintain the dignity and comfort of such patients until the end of their lives.
These patients are most suitable for management with the traditional methods such as incontinence sheets and pads. They should however be monitored every 12 hours (or more frequently, using clinical judgement) for any possible deterioration in their condition, which could indicate that management with an FMS might be more appropriate. While being monitored, these patients may be eligible for additional management strategies.
No matter what type of faecal management method is chosen for the individual patient, it is important to apply the appropriate skin care in order to protect the skin. This includes cleansing, moisturising and protecting the skin. 61
Summary and conclusions
AFId is described as two or more diarrhoea episodes over a 24-hour time period occurring in patients who are immobilised in the ICU. Causes of diarrhoea include nosocomial infections, such as C. difficile infection, and enteral feeding, with additional risk factors including surgical procedures in or around the anal region, antibiotics or chemotherapy, and medical conditions, such as graftversus-host disease and norovirus infection.
There are often clinical consequences of AFId. These include the risk of skin breakdown following overexposure of the skin to the moisture, enzymes and acid in liquid stool, and range from dermatitis to loss of tissue. There is the additional risk of spreading nosocomial pathogens, such as C. difficile, MRSA and VRE, to other patients and the caregivers in the ICU, which occurs through the contamination of the patients' environment and equipment.
In addition to the risk of contamination and physical trauma caused to the patient through AFId episodes, an additional consideration includes the psychological damage caused to the patient and the patient' s family through the embarrassment because of the AFId episodes.
Despite the important clinical complications associated with AFId, there has been a lack of guidelines or management strategies for the care of patients with AFId in the ICU. This has prompted the development of these recommendations, which are designed to help healthcare professionals to manage patients with AFId in order to avoid the associated clinical consequences. These recommendations are the product of a series of meetings between experts in ICU healthcare and infectious diseases from across Europe.
Before choosing the most appropriate management strategy, a comprehensive assessment of the patient should be carried out, taking into account individual risk factors and the severity of the patient' s condition. To aid the caregiver with the choice of faecal management options, the algorithm, which acknowledges different patient prognoses and infection risk, will provide guidance.
It is hoped that this document will help healthcare providers and ICU staff in the management of AFId, thereby reducing the physical and psychological problems associated with AFId episodes.
